Evaxion Biotech A/S - ADR

-0.01 (-0.45%)
Regulatory, Earnings Announcements

Evaxion Biotech A/S Reports Quarterly Loss Per Share Of $0.24

Published: 11/14/2022 13:41 GMT
Evaxion Biotech A/S - ADR (EVAX) - Evaxion Announces Third Quarter 2022 Financial Results and Business Update.
Evaxion Biotech A/s - Cash and Cash Equivalents of $17.9 Million Sufficient to Fund Operations Into Mid-2023.
Evaxion Biotech A/s - Increased Strategic Focus on Clinical Lead Oncology Assets and Partnering.
Evaxion Biotech A/s - Enrollment of First Patient in Our Global Phase 2b Clinical Trial of Evx-01.
Evaxion Biotech A/s - Qtrly Loss per Share $0.24.
Evaxion Biotech A/s - Anticipates Interim Topline Data Readout From Phase 2b Clinical Trial of Evx-01 in Second Half of 2023.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.26

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.30

More details on our Analysts Page.